21 Aug 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250821614975/en/PureTech-Showcases-Differentiated-Development-Strategy-Including-New-Patient-Preference-Insights-and-Spotlights-Phase-2b-Data-Positioning-Deupirfenidone-as-a-Potential-New-Standard-of-Care-in-IPF
13 Aug 2025
// FIERCE PHARMA
https://www.fiercebiotech.com/biotech/puretech-launches-celea-therapeutics-develop-highly-touted-lung-disease-candidate
21 May 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/puretech-shows-durability-pulmonary-fibrosis-candidate-deupirfenidone
01 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250501295892/en/PureTech-to-Present-Results-from-Phase-2b-ELEVATE-IPF-Trial-of-Deupirfenidone-LYT-100-at-the-American-Thoracic-Society-International-Conference
16 Dec 2024
// BUSINESSWIRE
08 Oct 2024
// BUSINESSWIRE